Value
8.6/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 7.2 |
| Fwd P/E | 9.5 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 8.2x
- ▸PEG: 0.05
- ▸Attractively valued
PHAT · Why this verdict
Why Phathom Pharmaceuticals (PHAT) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
PHAT's risk score sits below the engine's floor and options positioning signals heavy hedging, but a perfect earnings-beat streak, 104% revenue growth, and an elite Rule of 40 score temper the risk-driven exit signal.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The engine's risk score sits at 2.8, below its 3.0 minimum floor, triggering an extreme-risk exit signal despite otherwise strong fundamentals. Warnings | The risk score should rise above 3.0 as options positioning and volatility normalize over the next 12 months. | ↑Improving |
| CounterThe same risk floor breach coincides with an asymmetry ratio of 6.4 and 84% modeled upside, so the engine may be conflating high volatility with poor risk-adjusted opportunity. | ||
Risk notes flag an elevated put/call ratio of 7.20 alongside high implied volatility of 158%, both consistent with heavy options-driven hedging or speculative positioning. Risk breakdown | The put/call ratio should normalize toward 1.0 or below and implied volatility should compress over the next 12 months. | ↑Improving |
| CounterAs a binary biotech name, elevated options skew and IV are structural features of the sector rather than a company-specific red flag. | ||
Catalyst notes cite a perfect 4-quarter earnings beat streak, consistent with growth notes showing 104% YoY revenue growth. Catalyst breakdown | The beat streak should extend to a fifth consecutive quarter with a positive EPS surprise at the next report on 2026-08-06. | →Stable |
| CounterStrong top-line growth for an early-commercial biotech can still mask a cash-burning business model that depends on continued capital access. | ||
Quality notes flag PHAT as cash-burning, with free cash flow at -38% of revenue, despite an elite Rule of 40 score of 67. Quality breakdown | Free cash flow as a percentage of revenue should improve from -38% toward breakeven over the next 12 months. | →Stable |
| CounterAn elite Rule of 40 score of 67 suggests the combination of growth and margin trajectory is strong enough that current cash burn is a scaling investment rather than a structural weakness. | ||
The engine's risk score sits at 2.8, below its 3.0 minimum floor, triggering an extreme-risk exit signal despite otherwise strong fundamentals.
↑ImprovingWarnings
- Expectation
- The risk score should rise above 3.0 as options positioning and volatility normalize over the next 12 months.
CounterThe same risk floor breach coincides with an asymmetry ratio of 6.4 and 84% modeled upside, so the engine may be conflating high volatility with poor risk-adjusted opportunity.
Risk notes flag an elevated put/call ratio of 7.20 alongside high implied volatility of 158%, both consistent with heavy options-driven hedging or speculative positioning.
↑ImprovingRisk breakdown
- Expectation
- The put/call ratio should normalize toward 1.0 or below and implied volatility should compress over the next 12 months.
CounterAs a binary biotech name, elevated options skew and IV are structural features of the sector rather than a company-specific red flag.
Catalyst notes cite a perfect 4-quarter earnings beat streak, consistent with growth notes showing 104% YoY revenue growth.
→StableCatalyst breakdown
- Expectation
- The beat streak should extend to a fifth consecutive quarter with a positive EPS surprise at the next report on 2026-08-06.
CounterStrong top-line growth for an early-commercial biotech can still mask a cash-burning business model that depends on continued capital access.
Quality notes flag PHAT as cash-burning, with free cash flow at -38% of revenue, despite an elite Rule of 40 score of 67.
→StableQuality breakdown
- Expectation
- Free cash flow as a percentage of revenue should improve from -38% toward breakeven over the next 12 months.
CounterAn elite Rule of 40 score of 67 suggests the combination of growth and margin trajectory is strong enough that current cash burn is a scaling investment rather than a structural weakness.
Per-dimension breakdown
Quality
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.6 |
| FCF quality | 0.0 |
| Moat | 7.0 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -38% of revenue
- ▸Rule of 40: 67 (elite)
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 104% YoY
Momentum
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 6.8 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -1.1%/30d — confirmed downtrend
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.2 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Analyst upside: 103%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.6 |
| quality rank | 0.7 |
| growth rank | 8.4 |
- ▸Industry growth leader
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.1 |
| support resistance | 3.7 |
| 52w position | 2.7 |
| gap | 6.0 |
Risk (lower is worse)
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 2.1 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 6.7 |
| implied vol | 0.0 |
| beta | 10.0 |
- ▸High short interest: 16%
- ▸High IV: 109%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Perfect beat streak: 4Q
- ▸Earnings in 6 days
How the verdict was assembled
Engine trigger
Mixed signals. Hold existing position.
Engine technical detail
verdict_path:
L4:PATH_F_HOLD_DEFAULTPassed (7)
- MOMENTUM:5.5>=4.5
- ASYMMETRY:5.4>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:6d<=7d
Warning (2)
- MOMENTUM:5.5<5.5 (soft — BUY_NOW allowed but watch)
- DEATH_CROSS:momentum=5.5>=5.0 recovering
Reward-to-Risk
5.42
Upside
+76.7%
Downside
14.1%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 55
EdgeInst Constrain — Small cap ($0.9B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The default F-path HOLD fired without any positive-conviction gate triggering — no momentum acceleration, no quality+value crossover, no setup recognition. Highest-clear gate: MOMENTUM:5.5>=4.5. Top dim: Growth at 10.0; weakest: Risk (lower is worse) at 3.1. The engine's read is one of pattern absence — no directional conviction in either direction at current asymmetry.
The strongest dimensions are Growth at 10.0, Value at 8.6, and Sentiment at 7.9; the weakest are Risk (lower is worse) at 3.1, Technical at 3.9, and Quality at 4.5. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 5.42 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Risk Below Floor
Trip ifRisk score rises above 3.0 from the current 2.8, clearing the engine's minimum risk floor.
- P2Elevated Put Call And Implied Vol
Trip ifPut/call ratio falls below 2.0 from the current 7.20, and implied volatility compresses below 80%.
- P3Perfect Earnings Beat Streak With Strong Growth
Trip ifEPS surprise falls below 0% (a miss) at the August 6, 2026 earnings report, breaking the 4-quarter beat streak.
- P4Cash Burning Business Model
Trip ifFree cash flow as a percentage of revenue rises above 0%, turning cash-flow positive from the current -38%.